Alpha -Tocopherol Apple Cider Vinegar Arsenic Trio

證據等級: L5

預測適應症: 0 個

Multi-Component Complex (Arsenic Trioxide + 20 Ingredients): No Registered Indication → No TxGNN Prediction Generated

One-Sentence Summary

This entry describes a 21-component mixture containing both a known cytotoxic agent (Arsenic Trioxide) and a range of nutritional/herbal ingredients; it has no regulatory registration in the United States and no original indications on record. The TxGNN pipeline generated no predicted indications for this entry, likely because the multi-ingredient string could not be resolved to a single DrugBank ID. Without a matchable identity or predicted target, a formal repurposing evaluation cannot be completed at this time.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	None generated
TxGNN Prediction Score	N/A
Evidence Level	N/A — No prediction produced
US Market Status	Not marketed (0 NDAs)
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

The query was submitted as a single concatenated string of 21 distinct ingredients:

α-Tocopherol · Apple Cider Vinegar · Arsenic Trioxide · Ascorbic Acid · Ascorbyl Palmitate · Astragalus Root · Biancaea decapetala Root Bark · Bryonia alba Root · Citrus paradisi Seed · Curcumin · Curdlan · Drimia maritima Bulb · Garlic · Glutathione · Maitake · Olea europaea Leaf · Oregano · Potassium Carbonate · Pyridoxine · Rumex crispus Root · Zinc Picolinate

The TxGNN model requires a single, resolvable DrugBank ID as input. Because this entry could not be mapped to any DrugBank record (drugbank_id: null), the prediction pipeline produced no candidates. Three data gaps are blocking further progress:

No DrugBank ID — The compound string matches no single entity in the knowledge graph.
No MOA data — Without a mechanism, pathway-level reasoning is unavailable.
No original indication — There is no therapeutic anchor from which to extrapolate.

It is worth noting that one ingredient — Arsenic Trioxide — is a well-characterized antineoplastic agent (Trisenox®, NDA 021248) approved for Acute Promyelocytic Leukemia (APL). If the intent is to evaluate Arsenic Trioxide for repurposing, it should be submitted as a standalone query under its own DrugBank ID (DB01169).

Clinical Trial Evidence

Currently no related clinical trials registered (no predicted indication to search against).

Literature Evidence

Currently no related literature available (no predicted indication to search against).

US Market Information

This product has no US regulatory filings. Zero NDAs were found for the combined ingredient string.

Note: Arsenic Trioxide as a standalone drug is marketed in the US (Trisenox®, NDA 021248, indication: APL). If Arsenic Trioxide is the active ingredient of interest, it should be evaluated separately.

Cytotoxicity

This section is included because the mixture contains Arsenic Trioxide, a recognized antineoplastic agent.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Arsenical / Differentiation agent
Myelosuppression Risk	Moderate — leukocytosis during induction is characteristic; monitor for differentiation syndrome
Emetogenicity Classification	Low to Moderate
Monitoring Items	ECG (QTc interval), serum electrolytes (K⁺, Mg²⁺, Ca²⁺), CBC with differential, hepatic function
Handling Protection	Arsenic Trioxide must be handled under cytotoxic drug handling regulations; other herbal components in this formulation are unclassified

⚠️ Special concern: Arsenic Trioxide is associated with QT prolongation and potentially fatal arrhythmias. Co-administration with other QT-prolonging agents is contraindicated. The interaction profile with the 20 other ingredients in this mixture is unknown.

Safety Considerations

Please refer to the package insert for safety information.

Additional note: No DDI data was returned for this compound string. However, several individual ingredients carry clinically meaningful interactions. For example:

Arsenic Trioxide prolongs QT interval and interacts with antiarrhythmics, fluoroquinolones, and azole antifungals.

Grapefruit seed extract (Citrus paradisi) inhibits CYP3A4 and may alter plasma levels of co-administered drugs.

Garlic and Curcumin have antiplatelet effects and may potentiate anticoagulant therapy. These individual interactions were not captured because the system treated all 21 components as a single unresolvable entity.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline could not resolve this 21-ingredient string to a DrugBank entity and therefore produced no prediction. There is no regulatory basis, no predicted indication, and no evidence base on which to proceed. The presence of Arsenic Trioxide within an uncharacterized herbal mixture also raises unresolved safety questions that must be addressed before any repurposing pathway can be considered.

To proceed, the following is needed:

Decompose the query: Resubmit each ingredient as a separate TxGNN query. In particular, Arsenic Trioxide (DrugBank: DB01169) and Curcumin (DrugBank: DB11672) are individually profiled and will yield predictions.
Clarify product identity: Determine whether this represents a proprietary formulation, a compounded product, or a data entry artefact. Obtain the product’s brand name and manufacturer information.
Obtain regulatory data: If this mixture holds any foreign market authorization (e.g., traditional medicine registration), retrieve the indication text and safety labeling.
MOA documentation: For any ingredient identified as the primary active, retrieve mechanism of action from DrugBank or primary literature.
DDI assessment: Run individual DDI queries for Arsenic Trioxide and the CYP3A4-active botanicals (grapefruit seed, garlic, curcumin) before any clinical use scenario is modeled.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.